Preparation of a semisynthetic vaccine to Streptococcus pneumoniae type 3

Snippe, H.; Dam, J.E. Van; Houte, A J van; Willers, J. M. N.; Kamerling, J.P.; Vliegenthart, Johannes F.G.

doi:10.1128/iai.42.2.842-844.1983

Cited by 33 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results fit well to previous studies [14,15], wherein it was shown that a hexasaccharide derived from polysaccharide type 3 coupled without spacer as a pentasaccharide to KLH was capable of inducing protective immunity against type 3 pneumococci in mice.…”

Section: Streptococcus Pneumoniae Neisseria Meningitidis Haemophilus supporting

confidence: 91%

Carbohydrate based vaccines

Vliegenthart

2006

FEBS Letters

View full text Add to dashboard Cite

In the past decades, a gradual increase in the resistance to antibiotics has been observed, leading to a serious thread for successful treatment of bacterial infections. This feature in addition to difficulties in developing adequate drugs against (tropical) diseases caused by parasites has stimulated the interest in vaccines to prevent infections. In principle, various types of cell surface epitopes, characteristic for the invading organism or related to aberrant growth of cells, can be applied to develop vaccines. The progress in establishing the structure of carbohydrate immuno-determinants in conjunction with improvements in carbohydrate synthesis has rendered it feasible to develop new generations of carbohydrate-based vaccines.

show abstract

Section: Streptococcus Pneumoniae Neisseria Meningitidis Haemophilus supporting

confidence: 91%

Carbohydrate based vaccines

Vliegenthart

2006

FEBS Letters

View full text Add to dashboard Cite

show abstract

“…In the present study, NGL were constructed to promote both immunogenicity and antigenicity of these oligomannosides. Such an approach has been previously developed to produce antibodies against oligosaccharides from bacterial cell walls (28) or oligosaccharides isolated from different, human glycoproteins (29,32,36). However, the present use of 4-hexadecylaniline offers several advantages, since the binding of oligosaccharides to lipids is realized in a short time with a one-step procedure; the alkylaniline derivatives may also be easily detected by UV light.…”

Section: Discussionmentioning

confidence: 99%

“…In view of these problems, we attempted to develop a convenient model to determine the molecular basis of oligomannosidic recognition by experimental animal and human immune systems. Oligosaccharides were coupled to a lipid to form neoglycolipids (NGL) by a previously described method to study the antigenicity of oligosaccharides derived from human or bacterial glycoproteins (18,28,29,32,36). This work concerns oligosaccharides released from C. albicans PPM by mild acid hydrolysis (1,(24)(25)(26)33).…”

mentioning

confidence: 99%

Immunoreactivity of neoglycolipids constructed from oligomannosidic residues of the Candida albicans cell wall

et al. 1990

View full text Add to dashboard Cite

To establish a model to study the immunoreactivity of oligosaccharidic structures from the Candida albicans cell wall, we attempted to construct neoglycolipids with these residues by using oligomannosides released after mild acid hydrolysis of the phosphopeptidomannans isolated from yeast forms. From a mixture of manno-oligosaccharides ranging from mannobiose to mannononaose, the structure of a quantitatively major component (mannotriose) was determined to be Man (beta 1-2) Man (beta 1-2) Man alpha by 1H nuclear magnetic resonance analysis. After coupling of the pool of oligosaccharides to a lipid (4-hexadecylaniline), the synthesized molecules were injected into mice and rats. Antibody responses were detected on enzyme-linked immunosorbent assay plates coated with either phosphopeptidomannans or neoglycolipids. The hybrid molecules exhibited both immunogenicity and antigenicity. The kinetics of antibody responses as well as immunofluorescence patterns observed on whole C. albicans cells strongly mimicked results from the immunization of animals with natural antigens. Construction of neoglycolipids could therefore provide an interesting approach to the study of specific oligosaccharides of C. albicans and their recognition by the host immune system.

show abstract

“…Promising results have also been obtained following immunization with liposome-associated antigens; the oral (3,19,35,37,47) and parenteral (4,8,13,24,25,38,39,42) routes have been used for antigens of parasites (4,24,25,37,39), viruses (13,32), and bacteria (3,8,19,35,38,42,47). Their potential as adjuvants has been demonstrated in several studies, in which the use of liposome-associated antigens resulted in protective immunity (4,8,19,24,25,37,39,42) or at least cell-mediated (8) and humoral responses (3,13,38). The adjuvanticity of liposomes seems to depend on several factors including vesicle size and structure, lipid constitution, surface charge, antigen localization, the animal species immunized, route of immunization, and the distribution and number of lamellae.…”

mentioning

confidence: 99%

Antibody responses in the serum and respiratory tract of mice following oral vaccination with liposomes coated with filamentous hemagglutinin and pertussis toxoid

et al. 1993

View full text Add to dashboard Cite

Mice were orally vaccinated with liposomes coated with filamentous hemagglutinin (FHA) and detoxified pertussis toxin (PT) of BordeteUla pertussis. FHA-and PT-specific immunoglobulin G (IgG) was detected in serum, and both IgG and IgA were detected in lung washes following the immunization. Antibody responses in mice immunized with liposomes coated with FHA and PT were significantly higher than those in mice immunized with free FHA and PT, which demonstrated the adjuvanticity of the liposome carrier. The results indicate the potential usefulness of this approach for eliciting immune responses against FHA and PT (and perhaps other pertussis antigens) in humans and its possible utility in large-scale vaccination to protect against both B. pertussis infection and disease.

show abstract

Preparation of a semisynthetic vaccine to Streptococcus pneumoniae type 3

Abstract: A semisynthetic vaccine to Streptococcus pneumoniae type 3 has been developed. The hexasaccharide [3)GlcpA,(l4)Glcp(1]3 was isolated from a

Cited by 33 publications

References 2 publications

Carbohydrate based vaccines

Carbohydrate based vaccines

Immunoreactivity of neoglycolipids constructed from oligomannosidic residues of the Candida albicans cell wall

Antibody responses in the serum and respiratory tract of mice following oral vaccination with liposomes coated with filamentous hemagglutinin and pertussis toxoid

Contact Info

Product

Resources

About